Syneos Health, Inc. (SYNH)
| Market Cap | 7.88B |
| Revenue (ttm) | 4.42B |
| Net Income (ttm) | 192.79M |
| Shares Out | 104.17M |
| EPS (ttm) | 1.83 |
| PE Ratio | 41.26 |
| Forward PE | 18.42 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 2 |
| Last Price | $75.50 |
| Previous Close | $76.33 |
| Change ($) | -0.83 |
| Change (%) | -1.09% |
| Day's Open | 76.32 |
| Day's Range | 74.72 - 77.50 |
| Day's Volume | 3,098,760 |
| 52-Week Range | 30.02 - 81.35 |
MORRISVILLE, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization ...
MORRISVILLE, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization ...
Strategic Partnership Optimizes Integration for EHR Data and Delivers Remote Source Data Review Strategic Partnership Optimizes Integration for EHR Data and Delivers Remote Source Data Review
Seasoned Talent to Drive Expansion of Solutions at the Intersection of Value and Policy Seasoned Talent to Drive Expansion of Solutions at the Intersection of Value and Policy
Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.
Syneos Health (SYNH) delivered earnings and revenue surprises of 0.00% and 0.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Syneos Health (NASDAQ:SYNH) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share rose 7.77% year over year to $1.11, which beat the estimat...
Shared Commitment to Change, New Prescriber Realities, Model Evolution and Engagement Transformation Expected to be Critical Drivers Shared Commitment to Change, New Prescriber Realities, Mode...
MORRISVILLE, N.C., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and full ...
MORRISVILLE, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organiz...
Syneos Health (SYNH) is currently working on bringing greater flexibility to each customer study, based on data, people, process and technology.
Acquisition Enhances Company's Decentralized Solutions Offering by Strengthening Patient Focus Acquisition Enhances Company's Decentralized Solutions Offering by Strengthening Patient Focus
As of late, it has definitely been a great time to be an investor in Syneos Health (SYNH).
Let's see if Syneos Health (SYNH) stock is a good choice for value-oriented investors right now from multiple angles.
Syneos Health reduced its 2020 guidance but boosted its EBITDA margin guidance.
GREENWICH, Conn.--(BUSINESS WIRE)--Amulet Capital Partners Completes the Sale of Synteract to Syneos Health
MORRISVILLE, N.C., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it has completed the...
Unique Product Development Model Delivers Accelerated Growth
CAMBRIDGE, Mass. & MORRISVILLE, N.C.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company developing next-generation infectious disease and immuno-on...
Combination Offers Customers Access to Largest U.S. Oncology Real World Data Source and Best-in-Class Product Development Expertise for Faster, Smarter and More Patient-Centric Clinical Trials...
MORRISVILLE, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization c...
MORRISVILLE, N.C., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization c...
Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery in the Clinical Solutions segment and strategic partnerships.
MORRISVILLE, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization c...
MORRISVILLE, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization c...
MORRISVILLE, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization c...
MORRISVILLE, N.C., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Larry A...
MORRISVILLE, N.C., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organiz...
Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.
MORRISVILLE, N.C., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organiz...
Syneos Health, Inc. (SYNH) CEO Alistair Macdonald on Q3 2020 Results - Earnings Call Transcript
Shares of Syneos Health (NASDAQ:SYNH) moved higher by 3.2% in pre-market trading after the company reported Q3 results.
Syneos Health (SYNH) delivered earnings and revenue surprises of 15.56% and -1.92%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
GREENWICH, Conn.--(BUSINESS WIRE)--Amulet Capital Backed Synteract To Be Acquired by Syneos Health
Combination Enhances Syneos Health's Industry-Leading Position Across Fast-Growing Small to Mid-Sized Category Combination Enhances Syneos Health's Industry-Leading Position Across Fast-Growin...
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integrating Intelligence Across Channels, Technologies and Content Achieves Greater Precision, Efficiency and Effectiveness Integrating Intelligence Across Channels, Technologies and Content A...
Company Ranks Highest Among Biopharmaceutical Outsourcing Organizations Company Ranks Highest Among Biopharmaceutical Outsourcing Organizations
MORRISVILLE, N.C., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it was awarded the S...
MORRISVILLE, N.C., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2020 finan...
Syneos Health's (SYNH) over 70% of clinical businesses comprise essential therapeutic areas that are experiencing reduced impacts of coronavirus outbreak.
MORRISVILLE, N.C., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organizatio...
MORRISVILLE, N.C., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organizatio...
A Relative Strength Rating upgrade for Syneos Health shows improving technical performance. Will it continue?
MORRISVILLE, N.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Orga...
Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock?
MORRISVILLE, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Orga...
Syneos Health (SYNH) inks deal with Idorsia to commercialize the treatment for insomnia in the United States.
About SYNH
Syneos Health provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist custome... [Read more...]
| Industry Diagnostics & Research | IPO Date Nov 7, 2014 |
| CEO Alistair Macdonald | Employees 24,310 |
| Stock Exchange NASDAQ | Ticker Symbol SYNH |
Financial Performance
In 2020, Syneos Health's revenue was $4.42 billion, a decrease of -5.56% compared to the previous year's $4.68 billion. Earnings were $192.79 million, an increase of 46.88%.
Analyst Forecasts
According to 13 analysts, the average rating for Syneos Health stock is "Buy." The 12-month stock price forecast is 85.60, which is an increase of 13.38% from the latest price.